MLYS Stock Analysis: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$30.89
-1.20 (-3.74%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 11, 2026
9d
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $30.89, which is considered oversold relative to its 30-day fair value range of $32.03 to $35.99.
Technical Outlook: Technically, MLYS is in a downtrend. The price is currently testing key support at $30.79. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $50.88 (+64.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MLYS is in a downtrend. The price is currently testing key support at $30.79. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (11th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $50.88 (+64.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$32.03 -
$35.99
Company Quality Score
63/100
(BUY)
Options IV Signal
11th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
82.1%
Protect Your Profits
Holding MLYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 11th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 64.7% below Wall St target ($50.88)
- CAUTION: Recommendation downgraded due to -5.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$32.03 -
$35.99
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.86
(12.5%)
Support & Resistance Levels
Support Level
$30.79
Resistance Level
$34.65
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-13.86
Wall Street Target
$50.88
(+64.7%)
Last updated: January 31, 2026 9:32 PM ET
Data refreshes hourly during market hours. Next update: 10:32 PM
Data refreshes hourly during market hours. Next update: 10:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
2
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
10369 shares
2025-10-15
Adam Scott Levy
SELL
10758 shares
2025-10-13
Jon Congleton
SELL
15100 shares
2025-10-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
